止吐药:美国临床肿瘤学会临床实践指南更新
美国临床肿瘤学会召集专家组系统检索2009年11月至2016年6月的文献,共纳入41篇出版物。III期随机对照试验显示,在高致吐风险抗肿瘤药物治疗的成人患者中,止吐预防方案加用奥氮平可降低恶心可能性。指南更新包括奥氮平用于高致吐风险或突破性恶心呕吐成人、地塞米松仅第1天用于蒽环类联合环磷酰胺成人、以及卡铂曲线下面积≥4 mg/mL每分钟或大剂量化疗成人及高致吐风险儿科患者加用神经激肽1受体拮抗剂等推荐。
要点
- 高致吐风险抗肿瘤药物成人或突破性恶心呕吐成人,止吐方案加用奥氮平。
- 蒽环类联合环磷酰胺化疗成人,地塞米松仅第1天给药。
- 卡铂曲线下面积≥4 mg/mL每分钟或大剂量化疗成人及高致吐风险儿科患者,加用神经激肽1受体拮抗剂。
核心结论
- 指南更新推荐在高致吐风险抗肿瘤药物成人或突破性恶心呕吐成人中,止吐方案加用奥氮平。
- 推荐蒽环类联合环磷酰胺化疗成人地塞米松仅第1天给药。
- 推荐卡铂曲线下面积≥4 mg/mL每分钟或大剂量化疗成人及高致吐风险儿科患者加用神经激肽1受体拮抗剂。
- 专家组重申应使用适合所给抗肿瘤药物或放疗的最有效止吐方案,并应在初始治疗时使用,而非先用效果较差的治疗评估患者呕吐反应。
研究设计与样本
- 美国临床肿瘤学会召集专家组,对2009年11月至2016年6月的医学文献进行系统评价,共纳入41篇出版物。
主要发现
- 一项III期随机对照试验显示,在高致吐风险抗肿瘤药物治疗的成人患者中,止吐预防方案加用奥氮平可降低恶心可能性。
- 随机对照试验支持神经激肽1受体拮抗剂在化疗患者中扩大应用。
关键数值与推荐
- 高致吐风险抗肿瘤药物成人或突破性恶心呕吐成人:止吐方案加用奥氮平。
- 蒽环类联合环磷酰胺化疗成人:地塞米松仅第1天给药。
- 卡铂曲线下面积≥4 mg/mL每分钟或大剂量化疗成人,以及高致吐风险抗肿瘤药物儿科患者:加用神经激肽1受体拮抗剂。
- 低致吐风险放疗:现推荐仅用解救治疗。
- 放疗所致恶心呕吐:对解剖区域、风险等级和止吐给药方案进行了调整。
临床怎么用
- 应使用适合所给抗肿瘤药物或放疗的最有效止吐方案,并应在初始治疗时使用,而非先用效果较差的治疗评估患者呕吐反应。
- 低致吐风险放疗仅推荐解救治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical literature for the period of November 2009 to June 2016. Results Forty-one publications were included in this systematic review. A phase III randomized controlled trial demonstrated that adding olanzapine to antiemetic prophylaxis reduces the likelihood of nausea among adult patients who are treated with high emetic risk antineoplastic agents. Randomized controlled trials also support an expanded role for neurokinin 1 receptor antagonists in patients who are treated with chemotherapy. Recommendation Key updates include the addition of olanzapine to antiemetic regimens for adults who receive high-emetic-risk antineoplastic agents or who experience breakthrough nausea and vomiting; a recommendation to administer dexamethasone on day 1 only for adults who receive anthracycline and cyclophosphamide chemotherapy; and the addition of a neurokinin 1 receptor antagonist for adults who receive carboplatin area under the curve ≥ 4 mg/mL per minute or high-dose chemotherapy, and for pediatric patients who receive high-emetic-risk antineoplastic agents. For radiation-induced nausea and vomiting, adjustments were made to anatomic regions, risk levels, and antiemetic administration schedules. Rescue therapy alone is now recommended for low-emetic-risk radiation therapy. The Expert Panel reiterated the importance of using the most effective antiemetic regimens that are appropriate for antineoplastic agents or radiotherapy being administered. Such regimens should be used with initial treatment, rather than first assessing the patient's emetic response with less-effective treatment. Additional information is available at www.asco.org/supportive-care-guidelines and www.asco.org/guidelineswiki .
引用
- Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017. PMID: 28759346. doi:10.1200/JCO.2017.74.4789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。